His work on taste-masking via solventless coating technology has been commercially licensed by a global pharma company.
Engineered Particulates: Particle engineering for property enhancement and formation of nano-particles and structured particle composites, including films, for applications such as pharmaceutical, food, electronic and energetic materials.
His NSF-ERC leadership roles have led to significant impact on pharmaceutical industry through aligning high quality research with the NAE and NIH goals that include better medicines, medications the body can absorb and process efficiently, and designing therapies and dosages that are more precise and flexible.
These advancements are expected to have a broad societal impact through improved patient care, patient compliance and comfort and reduced manufacturing costs.
The company was formed to develop software for visualising in-process data using penalty matrices.
p-matrix Ltd also complements Dr Rajesh Ransing’s research efforts and co-ordinates 7Epsilon ( activities.
His interests include adaptation of MR sequences for free-breathing acquisition in sedated children, low radiation dose volumetric CT for pediatric applications, assessment of end-organ injury to the cardiovascular system from systemic diseases in children, contrast enhanced MR angiography, 3D image post-processing, and assessment of the value of imaging in pediatric disease.Improvement of powder flow via surface modification.Formation of stable nano and micro suspensions of poorly water-soluble drug particles for drug delivery applications. Industrial collaborations: Rolls Royce Plc, Transcendata Europe, GKN Squeezeform, Hydro Aluminium Extrusion Ltd, Doncasters Ltd, Astra Zeneca, Tritech Group, Informing Healthcare, TATA Steel, Mustang Marine Ltd (now Mainstay Marine Solutions), Meta Cause Solutions Ltd, Perpetuus Carbon Technologies Ltd, p-matrix Ltd, Cast Metal Federation, European Investment Casters Federation, Process Optimisation, Process Improvement, ISO9015 and 7Epsilon: Swansea University formed a spinout company Meta Cause Solutions Ltd to exploit patents and the outputs of the EPSRC (GR/R89912/01) and Welsh Government Projects (HE , HE , HE and HE TT 42).The company developed a Meta Cause process optimiser software using the assigned intellectual property.